Resources

September 17, 2019
Dear Chairman Alexander and Ranking Member Murray: On behalf of the undersigned organizations, we write to express urgent concern about a proposal in the President’s budget request that would undermine trust in the quality of biologic medicines.
September 9, 2019
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), today released Part II of its white paper series, “Failure to Launch,” finding that anti-competitive rebating tactics by brand-name manufacturers, coupled with policy failures and inadequate incentives for biosimilar use, stifle biosimilars adoption in the United States.
barriers to biosimilar adoption
September 9, 2019
This white paper will provide an explanation to the perverse mixture of brand-name biologic companies’ anti-competitive market access tactics and inadequate incentives that have cost the U.S. health care system billions of dollars in lost savings.
August 26, 2019
A coalition of over twenty stakeholders, including the American Cancer Society Cancer Action Network, CVS Health and USP submitted a letter to U.S. Health and Human Services Secretary Azar encouraging the use of biosimilars across Medicare programs.
July 23, 2019
In July of 2018, the U.S. Food and Drug Administration (FDA) released the Biosimilars Action Plan (BAP). At the one year mark, the agency has made significant progress with the BAP, but more can be done to ensure biosimilars are approved as efficiently as possible.
June 26, 2019
Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars Council to talk about biosimilars, their benefits and the hurdles to adoption in the United States.

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.

SIGN UP FOR OUR NEWSLETTER